REFERENCES
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. 2022. Cancer statistics,
2022. CA Cancer J Clin . 72(1):7-33.
2. Konstantinidis IT, Warshaw AL, Allen JN, et al. 2013. Pancreatic
ductal adenocarcinoma: is there a survival difference for R1 resections
versus locally advanced unresectable tumors? What is a ”true” R0
resection? Ann Surg . 257(4):731-736.
3. Ryan DP, Hong TS, Bardeesy N. 2014. Pancreatic adenocarcinoma.N Engl J Med . 371(11):1039-1049.
4. Oweira H, Petrausch U, Helbling D, et al. 2017. Prognostic value of
site-specific metastases in pancreatic adenocarcinoma: A Surveillance
Epidemiology and End Results database analysis. World J
Gastroenterol . 23(10):1872-1880.
5. Kurahara H, Maemura K, Mataki Y, et al. 2020. Lung recurrence and its
therapeutic strategy in patients with pancreatic cancer.Pancreatology . 20(1):89-94.
6. Kumar A, Dagar M, Herman J, Iacobuzio-Donahue C, Laheru D. 2015. CNS
involvement in pancreatic adenocarcinoma: a report of eight cases from
the Johns Hopkins Hospital and review of literature. J
Gastrointest Cancer . 46(1):5-8.
7. Yamaguchi K, Tanaka M. 2011. EBM-based Clinical Guidelines for
Pancreatic Cancer 2009 from the Japan Pancreas Society: a synopsis.Jpn J Clin Oncol . 41(7):836-840.
8. Murakami Y, Uemura K, Sudo T, et al. 2008. Adjuvant gemcitabine plus
S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.Am J Surg . 195(6):757-762.
9. Murakami Y, Uemura K, Sudo T, et al. 2009. Impact of adjuvant
gemcitabine plus S-1 chemotherapy after surgical resection for
adenocarcinoma of the body or tail of the pancreas. J Gastrointest
Surg . 13(1):85-92.
10. Buscail L. 2017. Commentary: Pancreatic cancer: is the worst to
come? Int J Epidemiol . 46(6):1774-1775.
11. Takahashi M, Nojima H, Kuboki S, et al. 2020. Comparing prognostic
factors of Glut-1 expression and maximum standardized uptake value by
FDG-PET in patients with resectable pancreatic cancer.Pancreatology . 20(6):1205-1212.
12. Miyazaki M, Yoshitomi H, Shimizu H, et al. 2014. Repeat
pancreatectomy for pancreatic ductal cancer recurrence in the remnant
pancreas after initial pancreatectomy: is it worthwhile? Surgery .
155(1):58-66.
13. Conroy T, Desseigne F, Ychou M, et al. 2011. FOLFIRINOX versus
gemcitabine for metastatic pancreatic cancer. N Engl J Med .
364(19):1817-1825.
14. Von Hoff DD, Ervin T, Arena FP, et al. 2013. Increased survival in
pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J
Med . 369(18):1691-1703.
15. Takahashi M, Yoshitomi H, Kato A, et al. 2019. A case of
successfully resected metachronous gastric and gallbladder metastases
from pancreatic body cancer. Surg Case Rep . 5(1):21.
16. Zheng B, Ohuchida K, Yan Z, Okumura T, Ohtsuka T, Nakamura M. 2017.
Primary Recurrence in the Lung is Related to Favorable Prognosis in
Patients with Pancreatic Cancer and Postoperative Recurrence.World J Surg . 41(11):2858-2866.
17. Okui M, Yamamichi T, Asakawa A, Harada M, Horio H. 2017. Resection
for Pancreatic Cancer Lung Metastases. Korean J Thorac Cardiovasc
Surg . 50(5):326-328.
18. Lemke J, Scheele J, Kapapa T, Wirtz CR, Henne-Bruns D, Korn{Lemke
m, M. 2013. Brain metastasis in pancreatic cancer. Int J Mol Sci .
14(2):4163-4173.
19. Matsumoto H, Yoshida Y. 2015. Brain metastasis from pancreatic
cancer: A case report and literature review. Asian J Neurosurg .
10(1):35-39.
20. Oka Y, Takano S, Kouchi Y, et al. 2021. Simultaneous brain and lung
metastases of pancreatic ductal adenocarcinoma after curative
pancreatectomy: a case report and literature review. BMC
Gastroenterol . 21(1):9.
21. Sasaki T, Sato T, Nakai Y, Sasahira N, Isayama H, Koike K. 2019.
Brain metastasis in pancreatic cancer: Two case reports. Medicine
(Baltimore) . 98(4):e14227.